阿托伐汀对冠心病患者血中趋化因子水平的影响

Effect of atorvastatin on plasma chemotatic factor levels in patients with coronary heart disease

目的观察冠心病患者血浆中趋化因子的变化,并进一步探讨阿托伐汀对趋化因子的影响。方法健康对照组25例,血脂正常的冠心病70例,随机将冠心病患者分为常规治疗组和阿托伐汀组,检测血浆中单核细胞趋化蛋白-1(monocyte chemoattract protein-1,MCP-1)、T细胞表达和分泌活化蛋白(regulated upon activation normal T cell expressed and secreted,RANTES)及白介素-8(interleukin-8,IL-8)水平。结果与健康对照组相比,冠心病患者血浆中MCP-1、RANTES、IL-8水平明显升高(P<0.01)。常规治疗组和阿托伐汀组治疗4周后MCP-1、RANTES、IL-8水平均有下降(P<0.05,P<0.01),阿托伐汀治疗组较常规治疗组降趋化因子的作用更明显(P<0.05)。结论阿托伐汀降低冠心病患者血浆中趋化因子水平,可能起到稳定粥样斑块的作用。

Objectives To observe plasma chemotatic factor levels in patients with coronary heart disease （CHD） and further to investigate the effect of atorvastatin on plasma chemotatic factor levels. Methods 25 healthy controls and 70 patients with CHD without hyperlipidemia were enrolled in the present study. Patients with CHD were randomly divided into routine group and atorvastatin group. The levels of plasma monocyte chemoattract protein-1 （MCP-1）, interleukin-8 （IL-8） and RANTES in controls and all patients were determined. Results Compared with control, the levels of MCP-1, IL-8 and RANTES were significantly elevated in patients with CHD （P〈0.01）. The elevated levels of chemotatic factor were partly attenuated by routine dosage of atorvastatin for 4 weeks （P〈0.05, P〈0.01）. However, the effect in atorvastatin group was more significant than that in routine therapy （P〈0.05）. Conclusions Atorvastatin may decrease the levels of chemotatic factor in patients with CHD to stabilize the atherosclerotic plaque.